BioNexus Exchange Rate Changes vs Change To Operating Activities Analysis

BGLC Stock

USD 4.55 0.35 7.14%

BioNexus Gene financial indicator trend analysis is way more than just evaluating BioNexus Gene Lab prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNexus Gene Lab is a good investment. Please check the relationship between BioNexus Gene Exchange Rate Changes and its Change To Operating Activities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Exchange Rate Changes vs Change To Operating Activities

Exchange Rate Changes vs Change To Operating Activities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNexus Gene Lab Exchange Rate Changes account and Change To Operating Activities. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between BioNexus Gene's Exchange Rate Changes and Change To Operating Activities is 0.4. Overlapping area represents the amount of variation of Exchange Rate Changes that can explain the historical movement of Change To Operating Activities in the same time period over historical financial statements of BioNexus Gene Lab, assuming nothing else is changed. The correlation between historical values of BioNexus Gene's Exchange Rate Changes and Change To Operating Activities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Exchange Rate Changes of BioNexus Gene Lab are associated (or correlated) with its Change To Operating Activities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change To Operating Activities has no effect on the direction of Exchange Rate Changes i.e., BioNexus Gene's Exchange Rate Changes and Change To Operating Activities go up and down completely randomly.

Correlation Coefficient

0.4

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Exchange Rate Changes

The impact of changes in foreign exchange rates on a company's financial position and results.

Change To Operating Activities

Most indicators from BioNexus Gene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNexus Gene Lab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

The current year's Issuance Of Capital Stock is expected to grow to about 6.9 M, whereas Tax Provision is forecasted to decline to 3,319.

	2022	2023	2024	2025 (projected)
Gross Profit	1.3M	1.3M	1.3M	1.1M
Total Revenue	10.9M	9.8M	9.5M	7.6M

Gross Profit Total Revenue

BioNexus Gene fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Other Liab	Property Plant And Equipment Net	Non Current Assets Total	Net Receivables	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant Equipment	Short Long Term Debt Total	Capital Lease Obligations
Total Assets		0.91	0.99	0.96	-0.9	-0.27	0.57	0.91	0.85	0.4	-0.73	0.92	1.0	0.94	-0.75	0.78	0.99	0.98	0.82	0.24	0.87	0.97	0.59	0.98	0.57	0.57
Total Current Liabilities	0.91		0.85	0.86	-0.72	-0.07	0.53	0.73	0.69	0.36	-0.72	1.0	0.93	0.79	-0.65	0.58	0.93	0.84	0.93	0.24	0.68	0.9	0.75	0.91	0.44	0.44
Total Stockholder Equity	0.99	0.85		0.95	-0.92	-0.31	0.56	0.94	0.87	0.4	-0.71	0.87	0.99	0.95	-0.76	0.81	0.97	0.99	0.76	0.24	0.89	0.96	0.52	0.97	0.59	0.59
Net Tangible Assets	0.96	0.86	0.95		-0.89	-0.39	0.57	0.85	0.77	0.45	-0.72	0.87	0.95	0.91	-0.78	0.87	0.96	0.95	0.81	0.03	0.88	0.95	0.57	0.93	0.56	0.56
Net Debt	-0.9	-0.72	-0.92	-0.89		0.6	-0.48	-0.98	-0.91	-0.24	0.71	-0.73	-0.88	-0.94	0.69	-0.8	-0.85	-0.91	-0.53	-0.09	-0.89	-0.82	-0.43	-0.82	-0.7	-0.7
Retained Earnings	-0.27	-0.07	-0.31	-0.39	0.6		-0.01	-0.51	-0.28	0.16	0.19	-0.09	-0.25	-0.44	0.15	-0.5	-0.23	-0.34	0.15	0.61	-0.56	-0.23	-0.12	-0.19	-0.79	-0.79
Accounts Payable	0.57	0.53	0.56	0.57	-0.48	-0.01		0.5	0.52	0.2	-0.81	0.55	0.58	0.64	-0.94	0.24	0.55	0.46	0.54	0.27	0.67	0.49	0.51	0.53	0.23	0.23
Cash	0.91	0.73	0.94	0.85	-0.98	-0.51	0.5		0.92	0.23	-0.71	0.74	0.9	0.96	-0.69	0.74	0.86	0.92	0.52	0.21	0.91	0.83	0.43	0.86	0.71	0.71
Cash And Short Term Investments	0.85	0.69	0.87	0.77	-0.91	-0.28	0.52	0.92		0.26	-0.71	0.7	0.84	0.85	-0.69	0.62	0.79	0.84	0.53	0.5	0.73	0.74	0.33	0.77	0.41	0.41
Common Stock Shares Outstanding	0.4	0.36	0.4	0.45	-0.24	0.16	0.2	0.23	0.26		-0.32	0.36	0.37	0.34	-0.35	0.49	0.42	0.48	0.46	0.16	0.27	0.36	0.16	0.44	-0.18	-0.18
Other Stockholder Equity	-0.73	-0.72	-0.71	-0.72	0.71	0.19	-0.81	-0.71	-0.71	-0.32		-0.73	-0.74	-0.85	0.87	-0.53	-0.68	-0.66	-0.57	-0.2	-0.75	-0.64	-0.41	-0.66	-0.33	-0.33
Total Liab	0.92	1.0	0.87	0.87	-0.73	-0.09	0.55	0.74	0.7	0.36	-0.73		0.94	0.81	-0.66	0.6	0.94	0.85	0.92	0.23	0.71	0.91	0.75	0.92	0.45	0.45
Total Current Assets	1.0	0.93	0.99	0.95	-0.88	-0.25	0.58	0.9	0.84	0.37	-0.74	0.94		0.93	-0.76	0.75	0.99	0.97	0.84	0.25	0.86	0.97	0.62	0.98	0.57	0.57
Common Stock	0.94	0.79	0.95	0.91	-0.94	-0.44	0.64	0.96	0.85	0.34	-0.85	0.81	0.93		-0.81	0.78	0.89	0.92	0.63	0.13	0.95	0.87	0.48	0.89	0.66	0.66
Other Current Liab	-0.75	-0.65	-0.76	-0.78	0.69	0.15	-0.94	-0.69	-0.69	-0.35	0.87	-0.66	-0.76	-0.81		-0.54	-0.73	-0.69	-0.64	-0.24	-0.81	-0.69	-0.45	-0.71	-0.32	-0.32
Other Liab	0.78	0.58	0.81	0.87	-0.8	-0.5	0.24	0.74	0.62	0.49	-0.53	0.6	0.75	0.78	-0.54		0.77	0.86	0.53	-0.15	0.74	0.81	0.15	0.75	0.48	0.48
Property Plant And Equipment Net	0.99	0.93	0.97	0.96	-0.85	-0.23	0.55	0.86	0.79	0.42	-0.68	0.94	0.99	0.89	-0.73	0.77		0.97	0.88	0.2	0.84	0.98	0.65	0.99	0.55	0.55
Non Current Assets Total	0.98	0.84	0.99	0.95	-0.91	-0.34	0.46	0.92	0.84	0.48	-0.66	0.85	0.97	0.92	-0.69	0.86	0.97		0.75	0.19	0.86	0.95	0.49	0.97	0.57	0.57
Net Receivables	0.82	0.93	0.76	0.81	-0.53	0.15	0.54	0.52	0.53	0.46	-0.57	0.92	0.84	0.63	-0.64	0.53	0.88	0.75		0.25	0.55	0.86	0.72	0.86	0.22	0.22
Short Term Investments	0.24	0.24	0.24	0.03	-0.09	0.61	0.27	0.21	0.5	0.16	-0.2	0.23	0.25	0.13	-0.24	-0.15	0.2	0.19	0.25		-0.04	0.15	0.0	0.23	-0.38	-0.38
Non Current Liabilities Total	0.87	0.68	0.89	0.88	-0.89	-0.56	0.67	0.91	0.73	0.27	-0.75	0.71	0.86	0.95	-0.81	0.74	0.84	0.86	0.55	-0.04		0.82	0.52	0.84	0.77	0.77
Inventory	0.97	0.9	0.96	0.95	-0.82	-0.23	0.49	0.83	0.74	0.36	-0.64	0.91	0.97	0.87	-0.69	0.81	0.98	0.95	0.86	0.15	0.82		0.56	0.98	0.55	0.55
Other Current Assets	0.59	0.75	0.52	0.57	-0.43	-0.12	0.51	0.43	0.33	0.16	-0.41	0.75	0.62	0.48	-0.45	0.15	0.65	0.49	0.72	0.0	0.52	0.56		0.64	0.52	0.52
Property Plant Equipment	0.98	0.91	0.97	0.93	-0.82	-0.19	0.53	0.86	0.77	0.44	-0.66	0.92	0.98	0.89	-0.71	0.75	0.99	0.97	0.86	0.23	0.84	0.98	0.64		0.56	0.56
Short Long Term Debt Total	0.57	0.44	0.59	0.56	-0.7	-0.79	0.23	0.71	0.41	-0.18	-0.33	0.45	0.57	0.66	-0.32	0.48	0.55	0.57	0.22	-0.38	0.77	0.55	0.52	0.56		1.0
Capital Lease Obligations	0.57	0.44	0.59	0.56	-0.7	-0.79	0.23	0.71	0.41	-0.18	-0.33	0.45	0.57	0.66	-0.32	0.48	0.55	0.57	0.22	-0.38	0.77	0.55	0.52	0.56	1.0

Click cells to compare fundamentals

BioNexus Gene Account Relationship Matchups

BioNexus Gene fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	10.1M	9.6M	8.7M	11.4M	10.4M	6.7M
Total Current Liabilities	3.4M	2.3M	2.0M	1.6M	2.0M	1.5M
Total Stockholder Equity	6.7M	7.2M	6.7M	9.7M	8.3M	5.0M
Net Tangible Assets	1.5M	1.1M	6.7M	7.2M	8.3M	8.7M
Net Debt	(2.7M)	(2.0M)	(2.1M)	(5.8M)	(4.2M)	(4.0M)
Retained Earnings	760.8K	1.5M	1.2M	(1.8M)	(3.4M)	(3.3M)
Cash	2.8M	2.1M	2.1M	5.9M	4.4M	2.5M
Cash And Short Term Investments	2.8M	2.1M	2.1M	5.9M	1.6M	2.1M
Common Stock Shares Outstanding	857.7K	1.4M	14.4M	1.7M	1.8M	2.8M
Liabilities And Stockholders Equity	10.1M	9.6M	8.7M	11.4M	10.4M	6.7M
Total Liab	3.5M	2.4M	2.1M	1.7M	2.1M	1.6M
Total Current Assets	8.0M	7.1M	6.0M	8.0M	7.4M	4.9M
Accumulated Other Comprehensive Income	133.7K	(100.3K)	(409.1K)	(677.3K)	(555K)	(527.3K)
Other Current Liab	50.1K	32.3K	103.4K	180.9K	301.3K	180.5K
Property Plant And Equipment Net	1.8M	1.7M	1.6M	1.7M	1.7M	1.3M
Non Current Assets Total	2.1M	2.4M	2.7M	3.4M	3.0M	2.0M
Net Receivables	4.0M	3.4M	2.9M	857.3K	1.6M	1.8M
Short Term Investments	2.1M	1.5M	1.5M	3.3M	(2.8M)	(2.7M)
Non Current Liabilities Total	79.5K	65.9K	71.1K	111.0K	159.7K	84.8K
Inventory	1.2M	1.5M	977.8K	1.1M	1.4M	860.4K
Other Current Assets	6.1M	147.1K	1.5M	122.4K	2.9M	1.6M
Property Plant Equipment	341.8K	336.5K	1.8M	1.6M	1.9M	961.7K
Short Long Term Debt Total	123.4K	76.9K	56.8K	133.4K	210.6K	121.4K
Capital Lease Obligations	123.4K	76.9K	56.8K	133.4K	210.6K	121.4K
Net Invested Capital	6.7M	7.2M	6.7M	9.7M	8.3M	6.5M
Long Term Investments	281.7K	749.0K	1.2M	1.7M	1.3M	812.6K
Net Working Capital	4.6M	4.8M	4.0M	6.4M	5.5M	4.3M
Short Term Debt	91.5K	79.0K	16.6K	47.8K	101.6K	66.0K
Property Plant And Equipment Gross	1.8M	1.6M	2.2M	2.3M	2.5M	2.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option

When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:

How To Invest In BioNexus

Details

Is BioNexus Stock a good investment?

Details

What is BioNexus Gene's Net Worth?

Details

Largest Specialty Chemicals Companies

View

Largest Basic Materials Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(1.19)

Revenue Per Share

5.178

Quarterly Revenue Growth

(0.10)

Return On Assets

(0.14)

The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

BioNexus Exchange Rate Changes vs Change To Operating Activities Analysis

Exchange Rate Changes vs Change To Operating Activities

Exchange Rate Changes vs Change To Operating Activities Correlation Analysis

Correlation Coefficient

Exchange Rate Changes

Change To Operating Activities

BioNexus Gene fundamental ratios Correlations

BioNexus Gene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNexus Gene fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Total Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity

Cash	- 0.98	Net Debt
Other Current Liab	- 0.94	Accounts Payable
Common Stock	- 0.94	Net Debt
Net Debt	- 0.92	Total Stockholder Equity
Non Current Assets Total	- 0.91	Net Debt
Cash And Short Term Investments	- 0.91	Net Debt